This CME/CE program is derived from content presented at the 2021 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC). The expert faculty, led by Fred D. Lublin, MD, will highlight the important emerging role of Bruton’s tyrosine kinase (BTK) inhibitors as the first brain penetrant disease modifying therapy that offers opportunities to improve neuroinflammation and neurodegeneration. The faculty will start by providing an overview of the BTK inhibitor science. Following, current clinical trial data regarding the safety and efficacy of BTK inhibitors will be analyzed, along with the clinical implications for the multiple sclerosis patient. The faculty will conclude with a discussion of best practices for shared decision making and patient education as it relates to these emerging therapies from an interprofessional perspective.
Neurologists, nurse practitioners, nurses, physician assistants, pharmacists, and other healthcare professionals involved in the management of patients with multiple sclerosis
- Review brain penetrating BTK inhibitor science, including neuroinflammation and neurodegeneration, as a therapeutic target to improve outcomes in patients with MS
- Analyze the current clinical trial data on the efficacy and safety of novel BTK inhibitors
- Utilize the comprehensive care team to apply treatment strategies for the application of BTK inhibitors and newer disease-modifying therapeutics to manage patients with MS
I. BTK Inhibitor Science: Adaptive and Innate Immunity, Neuroinflammation and Neurodegeneration – Benjamin Greenberg, MD
II. Clinical Trial Review and Analysis on the Safety and Efficacy of Novel BTK Inhibitors – Jiwon Oh, MD
III. Clinician/Patient Decision Making for Newer Therapeutics – Lessons Learned and Applied –Amy Perrin Ross, APN, MSN, CNRN, MSCN
IV. Panel Discussion – Fred D. Lublin, MD and Expert Faculty
Benjamin M. Greenberg, MD, MHS
Vice Chair of Translational Research
Department of Neurology and Neurotherapeutics
Director, Neuroimmunology Programs
UT Southwestern Medical Center
Children’s Medical Center
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Fred D. Lublin, MD||Consultant/Advisor: Acorda Therapeutics; Actelion Pharmaceuticals US, Inc.; Apitope; Atara Biotherapeutics; Avotres Inc.; Banner Life Sciences; Biogen; Brainstorm Cell Therapeutics; Bristol-Myers Squibb; Celgene Corporation; EMD Serono Inc.; Entelexo Biotherapeutics; Genentech, Inc.; GW Pharmaceuticals; Horizon Therapeutics plc; Immunic Therapeutics; Janssen Global Services, LLC; Jazz Pharmaceuticals; Labcorp; Mapi-Pharma Ltd.; MedDay Pharmaceuticals; Medimmune, LLC; Mylan; Neurogene; Novartis AG; Orion Biotechnology; Receptos; Roche; Sanofi Genzyme; Teva Pharmaceuticals; TG Therapeutics, Inc.; Viela Bio, Inc.
Grant/Research Support: Actelion Pharmaceuticals US, Inc.; Biogen; Brainstorm Cell Therapeutics; Novartis AG; Sanofi Genzyme
Stock Options: Avotres Inc.
|Benjamin M. Greenberg, MD, MHS||Consultant/Advisor: Alexion Pharmaceuticals; EMD Serono Inc.; Genentech, Inc.; Horizon Therapeutics plc; Immunovant, Inc.; IQVIA; Novartis AG; Roche; Sandoz International GmbH; Sanofi Genzyme; Signant Health
Grant/Research Support: Anokion; Clene Nanomedicine, Inc.
Jiwon Oh, MD, PhD
|Consultant/Advisor: Alexion Pharmaceuticals; Biogen; Bristol-Myers Squibb; EMD Serono Inc.; Novartis AG; Roche
Grant/Research Support: Biogen; EMD Serono Inc.; Roche
Amy Perrin Ross, APN, MSN, CNRN, MSCN
|Consultant/Advisor: Alexion Pharmaceuticals; Biogen; Bristol-Myers Squibb; EMD Serono Inc.; Genentech, Inc.; Greenwich Biosciences, Inc.; Horizon Therapeutics plc; Janssen Global Services, LLC; Mallinckrodt Pharmaceuticals; Novartis AG; Roche; Sanofi Genzyme; TG Therapeutics, Inc.|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Joseph Feick, PharmD; Gabrielle Fiorelli, CRNP and Nicole McMenamin state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this live material for a maximum of 1.0 CNE Contact Hour (Provider #P0491).
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-21-016-H04-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi Genzyme do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].